Works matching IS 08876924 AND DT 2009 AND VI 23 AND IP 11

Results: 34

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?

Published in:

2009

By:

Cardinaud, B.;
Moreilhon, C.;
Marcet, B.;
Robbe-Sermesant, K.;
LeBrigand, K.;
Mari, B.;
Eclache, V.;
Cymbalista, F.;
Raynaud, S.;
Barbry, P.

Publication type:

Letter

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.

Published in:

2009

By:

Familiades, J.;
Bousquet, M.;
Lafage-Pochitaloff, M.;
Béné, M-C.;
Beldjord, K.;
De Vos, J.;
Dastugue, N.;
Coyaud, E.;
Struski, S.;
Quelen, C.;
Prade-Houdellier, N.;
Dobbelstein, S.;
Cayuela, J.-M.;
Soulier, J.;
Grardel, N.;
Preudhomme, C.;
Cavé, H.;
Blanchet, O.;
Lhéritier, V.;
Delannoy, A.

Publication type:

journal article

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore...if you have myeloma’.

Published in:

2009

By:

Harvey, R. D.;
Nettles, J.;
Wang, B.;
Sun, S.-Y.;
Lonial, S.

Publication type:

Editorial

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.

Published in:

2009

By:

Roussou, M.;
Tasidou, A.;
Dimopoulos, M. A.;
Kastritis, E.;
Migkou, M.;
Christoulas, D.;
Gavriatopoulou, M.;
Zagouri, F.;
Matsouka, C.;
Anagnostou, D.;
Terpos, E.

Publication type:

Letter

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1.

Published in:

2009

By:

Terme, J.-M.;
Mocquet, V.;
Kuhlmann, A.-S.;
Zane, L.;
Mortreux, F.;
Wattel, E.;
Duc Dodon, M.;
Jalinot, P.

Publication type:

journal article

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.

Published in:

2009

By:

Gutman, D.;
Morales, A. A.;
Boise, L. H.

Publication type:

Letter

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2139, doi. 10.1038/leu.2009.136

By:

Colucci, S.;
Brunetti, G.;
Mori, G.;
Oranger, A.;
Centonze, M.;
Mori, C.;
Cantatore, F. P.;
Tamma, R.;
Rizzi, R.;
Liso, V.;
Zallone, A.;
Grano, M.

Publication type:

Article

A robust xenotransplantation model for acute myeloid leukemia.

Published in:

2009

By:

Sanchez, P. V.;
Perry, R. L.;
Sarry, J. E.;
Perl, A. E.;
Murphy, K.;
Swider, C. R.;
Bagg, A.;
Choi, J. K.;
Biegel, J. A.;
Danet-Desnoyers, G.;
Carroll, M.

Publication type:

journal article

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2102, doi. 10.1038/leu.2009.139

By:

Regis, G.;
Icardi, L.;
Conti, L.;
Chiarle, R.;
Piva, R.;
Giovarelli, M.;
Poli, V.;
Novelli, F.

Publication type:

Article

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2118, doi. 10.1038/leu.2009.145

By:

Plander, M.;
Seegers, S.;
Ugocsai, P.;
Diermeier-Daucher, S.;
Iványi, J.;
Schmitz, G.;
Hofstädter, F.;
Schwarz, S.;
Orsó, E.;
Knüchel, R.;
Brockhoff, G.

Publication type:

Article

Mutations of ASXL1 gene in myeloproliferative neoplasms.

Published in:

2009

By:

Carbuccia, N.;
Murati, A.;
Trouplin, V.;
Brecqueville, M.;
Adélaïde, J.;
Rey, J.;
Vainchenker, W.;
Bernard, O. A.;
Chaffanet, M.;
Vey, N.;
Birnbaum, D.;
Mozziconacci, M. J.

Publication type:

Letter

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2018, doi. 10.1038/leu.2009.144

By:

Farfsing, A.;
Engel, F.;
Seiffert, M.;
Hartmann, E.;
Ott, G.;
Rosenwald, A.;
Stilgenbauer, S.;
Döhner, H.;
Boutros, M.;
Lichter, P.;
Pscherer, A.

Publication type:

Article

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.

Published in:

2009

By:

Del Giudice, I.;
Osuji, N.;
Dexter, T.;
Brito-Babapulle, V.;
Parry-Jones, N.;
Chiaretti, S.;
Messina, M.;
Morgan, G.;
Catovsky, D.;
Matutes, E.

Publication type:

Letter

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2007, doi. 10.1038/leu.2009.140

By:

Böttcher, S.;
Stilgenbauer, S.;
Busch, R.;
Brüggemann, M.;
Raff, T.;
Pott, C.;
Fischer, K.;
Fingerle-Rowson, G.;
Döhner, H.;
Hallek, M.;
Kneba, M.;
Ritgen, M.

Publication type:

Article

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.

Published in:

2009

By:

Österborg, A.;
Foà, R.;
Bezares, R. F.;
Dearden, C.;
Dyer, M. J. S.;
Geisler, C.;
Lin, T. S.;
Montillo, M.;
van Oers, M. H. J.;
Wendtner, C.-M.;
Rai, K. R.;
Osterborg, A;
Foà, R

Publication type:

journal article

Defining origins of malignant B cells: a new circulating normal human IgM+D+ B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2075, doi. 10.1038/leu.2009.178

By:

Weston-Bell, N.;
Townsend, M.;
Di Genova, G.;
Forconi, F.;
Sahota, S. S.

Publication type:

Article

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2147, doi. 10.1038/leu.2009.147

By:

Dimopoulos, M. A.;
Chen, C.;
Spencer, A.;
Niesvizky, R.;
Attal, M.;
Stadtmauer, E. A.;
Petrucci, M. T.;
Yu, Z.;
Olesnyckyj, M.;
Zeldis, J. B.;
Knight, R. D.;
Weber, D. M.

Publication type:

Article

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).

Published in:

2009

By:

Nagel, I.;
Bug, S.;
Tönnies, H.;
Ammerpohl, O.;
Richter, J.;
Vater, I.;
Callet-Bauchu, E.;
Calasanz, M. J.;
Martinez-Climent, J. A.;
Bastard, C.;
Salido, M.;
Schroers, E.;
Martin-Subero, J. I.;
Gesk, S.;
Harder, L.;
Majid, A.;
Dyer, M. J. S.;
Siebert, R.;
Tönnies, H

Publication type:

Letter

Imatinib mesylate causes growth plate closure in vivo.

Published in:

2009

By:

Vandyke, K.;
Dewar, A. L.;
Fitter, S.;
Menicanin, D.;
To, L. B.;
Hughes, T. P.;
Zannettino, A. C. W.

Publication type:

Letter

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2034, doi. 10.1038/leu.2009.151

By:

Mason, K. D.;
Khaw, S. L.;
Rayeroux, K. C.;
Chew, E.;
Lee, E. F.;
Fairlie, W. D.;
Grigg, A. P.;
Seymour, J. F.;
Szer, J.;
Huang, D. C. S.;
Roberts, A. W.

Publication type:

Article

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Published in:

2009

By:

Zhou, Y.;
Barlogie, B.;
Shaughnessy, J. D.;
Shaughnessy, J D Jr

Publication type:

journal article

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2027, doi. 10.1038/leu.2009.148

By:

Cortelezzi, A.;
Pasquini, M. C.;
Gardellini, A.;
Gianelli, U.;
Bossi, A.;
Reda, G.;
Sarina, B.;
Musto, P.;
Barcellini, W.;
Neri, A.;
Deliliers, G. L.

Publication type:

Article

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).

Published in:

2009

By:

Nishioka, C.;
Ikezoe, T.;
Yang, J.;
Yokoyama, A.

Publication type:

Letter

The TLR1/2 agonist PAM3CSK4 instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2063, doi. 10.1038/leu.2009.155

By:

De Luca, K.;
Frances-Duvert, V.;
Asensio, M.-J.;
Ihsani, R.;
Debien, E.;
Taillardet, M.;
Verhoeyen, E.;
Bella, C.;
Lantheaume, S.;
Genestier, L.;
Defrance, T.

Publication type:

Article

Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.

Published in:

2009

By:

Lee, H. M.;
Wu, W.;
Wysoczynski, M.;
Liu, R.;
Zuba-Surma, E. K.;
Kucia, M.;
Ratajczak, J.;
Ratajczak, M. Z.

Publication type:

journal article

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.

Published in:

2009

By:

Bhat, R.;
Malinge, S.;
Gamis, A. S.;
Sorrell, A. D.;
Hilden, J. M.;
Ketterling, R. P.;
Paietta, E.;
Tallman, M. S.;
Crispino, J. D.

Publication type:

commentary

Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells.

Published in:

2009

By:

Shin, D. M.;
Zuba-Surma, E. K.;
Wu, W.;
Ratajczak, J.;
Wysoczynski, M.;
Ratajczak, M. Z.;
Kucia, M.

Publication type:

journal article

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis.

Published in:

2009

By:

Eberhart, K.;
Renner, K.;
Ritter, I.;
Kastenberger, M.;
Singer, K.;
Hellerbrand, C.;
Kreutz, M.;
Kofler, R.;
Oefner, P. J.

Publication type:

Letter

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

Published in:

2009

By:

Davies, A.;
Jordanides, N. E.;
Giannoudis, A.;
Lucas, C. M.;
Hatziieremia, S.;
Harris, R. J.;
Jørgensen, H. G.;
Holyoake, T. L.;
Pirmohamed, M.;
Clark, R. E.;
Mountford, J. C.;
Jørgensen, H G

Publication type:

journal article

Harmonization of molecular monitoring of CML therapy in Europe.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 1957, doi. 10.1038/leu.2009.168

By:

Müller, M. C.;
Cross, N. C. P.;
Erben, P.;
Schenk, T.;
Hanfstein, B.;
Ernst, T.;
Hehlmann, R.;
Branford, S.;
Saglio, G.;
Hochhaus, A.

Publication type:

Article

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.

Published in:

2009

By:

Hasegawa, H.;
Yamada, Y.;
Iha, H.;
Tsukasaki, K.;
Nagai, K.;
Atogami, S.;
Sugahara, K.;
Tsuruda, K.;
Ishizaki, A.;
Kamihira, S.

Publication type:

journal article

Proteasome inhibitors in the treatment of multiple myeloma.

Published in:

2009

By:

Shah, J. J.;
Orlowski, R. Z.

Publication type:

journal article

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.

Published in:

Leukemia (08876924), 2009, v. 23, n. 11, p. 2129, doi. 10.1038/leu.2009.161

By:

Eckerle, S.;
Brune, V.;
Döring, C.;
Tiacci, E.;
Bohle, V.;
Sundström, C.;
Kodet, R.;
Paulli, M.;
Falini, B.;
Klapper, W.;
Chaubert, A. B.;
Willenbrock, K.;
Metzler, D.;
Bräuninger, A.;
Küppers, R.;
Hansmann, M.-L.

Publication type:

Article

HTLV-I infection of WE17/10 CD4+ cell line leads to progressive alteration of Ca2+ influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation

Published in:

2009

By:

Akl, H;
Badran, B M;
El Zein, N;
Bex, F;
Sotiriou, C;
Willard-Gallo, K E;
Burny, A;
Martiat, P

Publication type:

Correction Notice

Works matching IS 08876924 AND DT 2009 AND VI 23 AND IP 11

miR-34b/miR-34c: a regulator of TCL1 expression in 11q− chronic lymphocytic leukaemia?

PAX5 mutations occur frequently in adult B-cell progenitor acute lymphoblastic leukemia and PAX5 haploinsufficiency is associated with BCR-ABL1 and TCF3-PBX1 fusion genes: a GRAALL study.

Commentary on Perrone et al.: ‘Vitamin C: not for breakfast anymore...if you have myeloma’.

Increased expression of macrophage inflammatory protein-1α on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma.

Inhibition of the hTERT promoter by the proto-oncogenic protein TAL1.

Acquisition of a multidrug-resistant phenotype with a proteasome inhibitor in multiple myeloma.

Soluble decoy receptor 3 modulates the survival and formation of osteoclasts from multiple myeloma bone disease patients.

A robust xenotransplantation model for acute myeloid leukemia.

IL-6, but not IFN-γ, triggers apoptosis and inhibits in vivo growth of human malignant T cells on STAT3 silencing.

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.

Mutations of ASXL1 gene in myeloproliferative neoplasms.

Gene knockdown studies revealed CCDC50 as a candidate gene in mantle cell lymphoma and chronic lymphocytic leukemia.

B-cell prolymphocytic leukemia and chronic lymphocytic leukemia have distinctive gene expression signatures.

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis.

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia.

Defining origins of malignant B cells: a new circulating normal human IgM<sup>+</sup>D<sup>+</sup> B-cell subset lacking CD27 expression and displaying somatically mutated IGHV genes as a relevant memory population.

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma.

Biallelic inactivation of TRAF3 in a subset of B-cell lymphomas with interstitial del(14)(q24.1q32.33).

Imatinib mesylate causes growth plate closure in vivo.

The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.

The molecular characterization and clinical management of multiple myeloma in the post-genome era.

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study.

Sunitinib, an orally available receptor tyrosine kinase inhibitor, induces monocytic differentiation of acute myelogenous leukemia cells that is enhanced by 1,25-dihydroxyvitamin D(3).

The TLR1/2 agonist PAM<sub>3</sub>CSK<sub>4</sub> instructs commitment of human hematopoietic stem cells to a myeloid cell fate.

Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes.

Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.

Novel epigenetic mechanisms that control pluripotency and quiescence of adult bone marrow-derived Oct4(+) very small embryonic-like stem cells.

Low doses of 2-deoxy-glucose sensitize acute lymphoblastic leukemia cells to glucocorticoid-induced apoptosis.

Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters.

Harmonization of molecular monitoring of CML therapy in Europe.

Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.

Proteasome inhibitors in the treatment of multiple myeloma.

Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.

HTLV-I infection of WE17/10 CD4<sup>+</sup> cell line leads to progressive alteration of Ca<sup>2+</sup> influx that eventually results in loss of CD7 expression and activation of an antiapoptotic pathway involving AKT and BAD which paves the way for malignant transformation